CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
CVI Accepts, published online ahead of print on 16 April 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00003-08v1
15/6/946    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Omland, K. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omland, K. S.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00003-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Interlaboratory Comparison of the Anthrax Lethal Toxin Neutralization Assay used to Assess Functional Antibodies in Multiple Species

Kristian S. Omland, April Brys, David Lansky, Kristin Clement, Freyja Lynn* and the Participating Laboratories

Precision Bioassay, Burlington, VT; Battelle Eastern Science and Technology Center, Aberdeen MD; Battelle Biomedical Research Center, West Jefferson, OH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD; Centers for Disease Control and Prevention, Atlanta, GA; Emergent BioSolutions, Lansing MI; VaxGen Inc., Brisbane, CA; USAMRIID, Fort Detrick, MD

* To whom correspondence should be addressed. Email: lynnf{at}niaid.nih.gov.


   Abstract

The anthrax lethal toxin neutralization assay (TNA) will likely be used as a correlate of protection to bridge efficacy of new anthrax vaccines in animal models to immunogenicity in humans. TNA data are being generated in several different laboratories to measure the immune responses in rabbits, nonhuman primates and humans. In order to compare data among species and laboratories, a collaborative study was conducted in which 108 samples from the three species were analyzed in seven independent laboratories. Six of the seven laboratories had participated in an interlaboratory technology transfer of the TNA. Analysis of the titration curves generated by samples from each species indicated that the behavior of the samples from all species were similar; the upper and lower asymptotes and the slopes of the curves were less than 30% divergent from a human reference material. Dilutional linearity of samples from each species was also similar, with spike to ED50 slopes of less than 1.2 for all species. Agreement among the laboratories to consensus values was within 10% of the ED50 values for all samples, and within 7.5% of the NF50 values for all samples. The relative standard deviation combining all laboratories and species was 45% for the ED50 values and 35% for the NF50 values. These precision data suggest that the NF50 readout may normalize values generated by different laboratories. This study demonstrates that the TNA is a panspecies assay that can be performed in several different laboratories with a high degree of quantitative agreement and precision.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.